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ABSTRACT The objective of this study was to assess the association between previous
antibiotic use, particularly long-term prophylaxis, and the occurrence of subsequent
resistant infections in children with index infections due to extended-spectrum-
cephalosporin-resistant Enterobacteriaceae. We also investigated the concordance
of the index and subsequent isolates. Extended-spectrum-cephalosporin-resistant
Escherichia coli and Klebsiella spp. isolated from normally sterile sites of patients
aged 22 years were collected along with associated clinical data from four
freestanding pediatric centers. Subsequent isolates were categorized as concor-
dant if the species, resistance determinants, and fumC-ﬁmH (E. coli) or tonB (Kleb-
siella pneumoniae) type were identical to those of the index isolate. In total, 323
patients had 396 resistant isolates; 45 (14%) patients had 1 subsequent resis-
tant infection, totaling 73 subsequent resistant isolates. The median time be-
tween the index and ﬁrst subsequent infections was 123 (interquartile range, 43
to 225) days. In multivariable Cox proportional hazards analyses, patients were
2.07 times as likely to have a subsequent resistant infection (95% conﬁdence in-
terval, 1.11 to 3.87) if they received prophylaxis in the 30 days prior to the index
infection. In 26 (58%) patients, all subsequent isolates were concordant with
their index isolate, and 7 (16%) additional patients had at least 1 concordant
subsequent isolate. In 12 of 17 (71%) patients with E. coli sequence type 131
(ST131)-associated type 40-30, all subsequent isolates were concordant. Subse-
quent extended-spectrum-cephalosporin-resistant infections are relatively fre-
quent and are most commonly due to bacterial strains concordant with the in-
dex isolate. Further study is needed to assess the role prophylaxis plays in these
resistant infections.
KEYWORDS antibiotic resistance, pediatric infectious disease
Infections caused by extended-spectrum-cephalosporin-resistant (ESC-R) Escherichiacoli and Klebsiella species, including extended-spectrum beta-lactamase (ESBL)- and
AmpC-producing organisms, are an emerging problem in children. These infections are
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increasing in frequency and are associated with prolonged hospitalization and mortal-
ity (1–6). Additionally, antimicrobial resistance among these organisms is often medi-
ated by mobile genetic elements, resulting in multiple avenues for resistance transfer
and infection transmission.
Subsequent resistant infections, due either to the same organism as the initial
infection or to a new resistant organism, are a concerning clinical outcome associated
with ESC-R Enterobacteriaceae infection. Reported rates of subsequent ESC-R infections
range between 16% and 45% (7–11), but few studies have evaluated potential risk
factors for subsequent ESC-R infections (9, 12). In our prior single-center study, we
identiﬁed the receipt of 14 days of antibiotics in the previous 91 days as an
independent predictor for subsequent ESC-R urinary tract infection (UTI) in children.
The vast majority (91%) of the patients who received 14 days of antibiotics in the
previous 91 days received long-term prophylaxis and were likely driving this associa-
tion; however, this study was limited by a small sample size (9). Long-term prophylactic
antibiotics are often prescribed for children with certain UTI risk factors and/or frequent
UTIs (13, 14), and this prolonged exposure may increase the risk of multiple ESC-R
infections (1, 9).
Few studies of ESC-R infections have compared the molecular characteristics be-
tween index and subsequent isolates in adults or children (9, 11). In our previous study,
we found that the majority of patients had at least one subsequent isolate with the
same molecular characteristics as the index isolate (9).
The objective of this study was to assess the association between previous antibiotic
use, including a separate examination of long-term prophylaxis, and the occurrence of
subsequent ESC-R infections among a cohort of patients with index ESC-R E. coli and
Klebsiella sp. infections identiﬁed at four U.S. tertiary care pediatric centers. Further-
more, we compared the species, bacterial sequence types (fumC-ﬁmH type for E. coli or
tonB type for Klebsiella pneumoniae), and resistance determinants to evaluate the
concordance between index and subsequent isolates.
RESULTS
A total of 323 patients with 396 ESC-R E. coli (83%) or Klebsiella sp. (17%) isolates
were identiﬁed; 45 (14%) patients had 1 subsequent ESC-R E. coli and Klebsiella sp.
infection, totaling 73 subsequent ESC-R E. coli and Klebsiella spp. isolates. The median
number of subsequent infections for patients was 1 (interquartile range [IQR], 1 to 2
infections); the median number of days between the index and the ﬁrst subsequent
infections was 123 (IQR, 43 to 225 days).
Demographics and clinical characteristics. The median age of patients with
subsequent infections was 5.1 (IQR, 1.7 to 10.2) years and was 4.9 (IQR, 1.1 to 11.7) years
for patients without a subsequent infection. Urine was the source of 348 (88%) isolates,
and 344 (99%) of these met the criteria for likely UTI. Of the 344 that met the criteria
for likely UTI, 244 (71%) met microbiological criteria and the patients had symptoms of
UTI, 96 (28%) met the microbiological criteria and symptom data were not available,
and 4 (1%) met the criteria based on symptoms alone (cultures did not meet standard
microbiological criteria). Of the 248 patients with symptoms reported, 144 (58%) had
fevers, 66 (27%) had abdominal or ﬂank pain, 66 (27%) had dysuria, frequent or urgent
urination, or changes in continence patterns, 50 (20%) had changes in the color or odor
of urine, 16 (6%) had hematuria, and 27 (11%) had vomiting.
Patients with subsequent ESC-R infections were more likely than those with only one
isolate to have been hospitalized in the year prior to the index infections and have
underlying medical conditions (Table 1). Furthermore, patients with subsequent ESC-R
infections were more likely than those without to have received any antibiotics in the
30 days prior to the index (62% versus 46%, respectively) and to have received
prophylactic antibiotics in the 30 days prior to the index (47% versus 22%, respectively)
(Table 2). Of the 81 patients who received prophylactic antibiotics, 72 (90%) were on
the prophylactic regimen for the entire 30-day period and the remaining 9 (10%)
patients had been receiving the prophylactic regimen for several months and discon-
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tinued the regimen during the 30-day period. In the Cox proportional hazards analyses,
after adjusting for potential confounders, receipt of any antibiotics in the 30 days prior
to their index infection was not statistically signiﬁcantly associated with having a
subsequent resistant infection (Table 2). However, when examining prophylaxis only,
TABLE 1 Demographic and clinical characteristics of children with and without
subsequent infectionsa
Characteristic
No. (%) unless otherwise noted
P value
Subsequent infection?
Yes (n  45) No (n  278)
Median age (years) 5.1 4.9 0.98
IQRb 1.7–10.2 1.1–11.7
Female sex 32 (71) 202 (73) 0.83
Hispanic ethnicity 7 (16) 39 (15) 0.90
Race 0.50
Caucasian 29 (64) 154 (59)
African American 4 (9) 46 (18)
Asian 10 (22) 49 (19)
Native American 0 (0) 6 (2)
Paciﬁc Islander 2 (4) 6 (2)
More than one race 0 (0) 1 (0)
Site of index infection 0.37
Urine 38 (85) 246 (89)
Blood 6 (13) 20 (7)
Other 1c (2) 12d (4)
Onsete 0.01
Community associated 1 (2) 91 (33)
Healthcare associated 39 (87) 136 (49)
Hospital associated 5 (11) 51 (18)
Previously hospitalized in last year 28 (62) 123 (44) 0.03
Median hospitalizations in last year 1 2 0.56
IQR 1–5 1–4
Medical condition category 0.01
Urological 32 (71) 87 (31)
Otherf 10 (22) 84 (30)
Immunocompromisedg 9 (20) 54 (20) 0.53
In-dwelling devicesh 23 (51) 103 (37) 0.10
Central venous catheter 10 (22) 49 (18)
Foley catheter 4 (9) 15 (5)
Nasogastric tube 9 (20) 49 (18)
Other 11 (24) 42 (41)
aTable does not account for missing data.
bIQR, interquartile range.
cPeritoneal ﬂuid (n  1).
dPeritoneal ﬂuid (n  5), bone (n  3), surgical wound (n  3), and cerebrospinal ﬂuid (n  1).
eHospital-associated onset deﬁned as a culture obtained 48 h after hospitalization from a patient without
signs or symptoms of infection on hospital admission or 48 h after hospital discharge from a patient
without signs and symptoms of infection on admission. Community-associated onset deﬁned as a culture
obtained in an outpatient setting or 48 h after hospital admission from an otherwise healthy patient
without hospitalization in the previous year. Health care-associated onset deﬁned as a culture obtained in
an outpatient setting or 48 h after hospitalization from a patient who had been hospitalized in the last
year and/or had a chronic medical condition requiring frequent contact with health care facilities or
prolonged/recurrent antibiotic courses.
fIncludes neuromuscular, cardiovascular, respiratory, gastrointestinal, hematology/oncology, metabolic, and
other congenital/chromosomal and rheumatologic conditions.
gIncludes malignancy, immunosuppression (chemotherapy, glucocorticoids 2 mg/kg for 2 weeks, tumor
necrosis factor [TNF] inhibitors, calcineurin inhibitors, mycophenolate mofetil [MMF], antineoplastic agents),
and any transplant.
hTotal is 100% as patients could have more than one device.
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patients were 2.07 times more likely (95% conﬁdence interval [CI], 1.11 to 3.87) to have
subsequent ESC-R infections if they received prophylaxis in the 30 days prior to the
index ESC-R infections, even after adjusting for potential confounders.
Patients with index infections due to ESC-R K. pneumoniae, as opposed to E. coli,
were overrepresented in the group with subsequent infections (P  0.03) (Table 3).
When comparing strains of E. coli, fumC-ﬁmH type 40-30 (also known as sequence type
131 [ST131]-H30 or clade C) was signiﬁcantly more common in patients with subse-
quent ESC-R infections (P  0.01) (Table 3).
Comparison of microbiological characteristics of index and subsequent iso-
lates. In 26 (58%) of 45 patients with subsequent infections due to ESC-R organisms, all
subsequent isolates were concordant with their index isolate (Table 4; see also Table S2
in the supplemental material). An additional 7 patients (16%) had at least 1 subsequent
isolate that was concordant with the index isolate. The remaining 12 (26%) patients had
subsequent isolates that were only discordant with the index isolates. In total, 48 (66%)
TABLE 2 Antibiotic exposure in pediatric patients with and without subsequent infections
Exposure
No. (%) Hazard ratio (95% CI)
Subsequent infection?
Univariate MultivariateaYes (n  45) No (n  278)
Any antibiotic in last 30 daysb 28 (62) 128 (46) 1.84 (1.01–3.36) 1.16 (0.61–2.21)
Prophylaxis in last 30 days 21 (47) 60 (22) 2.80 (1.56–5.03) 2.07 (1.11–3.87)
aAdjusted for any medical condition, hospitalized in year prior to index infection, indwelling device, and
immunosuppression.
bIncludes treatment and prophylaxis in the 30 days prior to the index infection.
TABLE 3Microbiological proﬁles of index isolates of children with and without
subsequent infections
Characteristic
No. (%)
P value
Subsequent infection?
Yes (n  45) No (n  278)
Species 0.03
E. coli 33 (73) 240 (86)
K. pneumoniae 12 (27) 38 (14)
E. coli fumC-ﬁmH sequence typea 0.005
Alleles 40-30 17 (52) 66 (28)
Others 16 (48) 174 (72)
K. pneumoniae tonB sequence typeb 0.24
Allele 39 2 (17) 2 (5)
Others 10 (83) 36 (95)
Resistance phenotype 0.84
ESBL 32 (71) 179 (64)
AmpC 11 (25) 83 (30)
ESBL and AmpC 1 (2) 5 (2)
Carbapenem resistant 1 (2) 8 (3)
Undetermined 0 3 (1)
Resistance determinantsc
CTX-M-15 20 (44) 103 (37) 0.34
CTX-M others 9 (20) 61 (22) 0.77
CMY-2 9 (20) 71 (26) 0.42
DHA 1 (2) 4 (1) 0.53
FOX 1 (2) 3 (1) 0.45
SHV 4 (9) 12 (4) 0.25
None detected 5 (11) 32 (12) 0.99
aDenominator is all E. coli isolates.
bDenominator is all K. pneumoniae isolates.
cTotal is 100% as more than one determinant can be detected.
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of subsequent isolates were concordant with the index isolates and the remaining 25
isolates (34%) were discordant.
The discordances between index and subsequent isolates included instances of
different resistance determinants with the same fumC-ﬁmH or tonB type (n  11
isolates), different fumC-ﬁmH or tonB types with shared resistance determinants (n  5
isolates), different species with a shared resistance determinant (n  6 isolates), and
both different resistance determinants and different fumC-ﬁmH or tonB types (n  3
isolates) (Table S2).
Of the 17 patients with index infections caused by E. coli fumC-ﬁmH type 40-30, in
12 (71%), all subsequent isolates were concordant with their index isolate (Table 4; see
also Table S1). An additional 3 (18%) patients had at least 1 subsequent isolate that was
concordant with the index isolate. The remaining 2 (12%) patients had isolates that
were only discordant to the index isolates. In total, 28 (80%) of the 35 fumC-ﬁmH type
40-30 subsequent isolates were concordant with the index isolates and the remaining
7 (20%) were discordant (Table S2).
Among the fumC-ﬁmH type 40-30 isolates, all instances of discordance between
subsequent and index isolates were instances of different resistance determinants with
the same fumC-ﬁmH type (40-30) (Table S2).
DISCUSSION
In this study, we observed that 14% of patients with an initial ESC-R infection
experienced a subsequent ESC-R infection during our observation period. Most patients
(58%) had only 1 subsequent infection, and the median time between the index and
the ﬁrst subsequent infections was 123 days. We found that previous antibiotic use and
prophylaxis use were associated with subsequent infections in univariate analyses, but
only prophylaxis remained an independent risk factor for subsequent infections after
adjusting for potential confounders. Subsequent infections were most commonly (66%)
due to bacterial strains of the same fumC-ﬁmH or tonB type and resistance determinants
as index ESC-R isolates. E. coli ST131-associated fumC-ﬁmH type 40-30, also known as
ST131-H30 or clade C, had an even higher ratio of concordance (80%) between index
and subsequent isolates.
Other studies have identiﬁed antibiotic use as an independent risk factor for
subsequent ESC-R Enterobacteriaceae infections, but variations in study population and
design make direct comparisons to these studies challenging. A previous study from
our research group found that receipt of 14 days of antibiotics within the 3 months
TABLE 4 Distribution of resistance determinants by species and sequence type among index and subsequent isolate series
Index isolate
sequence type Determinant
No. of
patients
Subsequent isolate series
Concordant
isolates
Mixed discordant and concordant isolates
Discordant isolates
No. of
patients
No. of isolates
No. of
patients
No. of
isolates Total Concordant Discordant
No. of
patients
No. of
isolates
E. coli fumC-ﬁmH
40-30 CTX-M-15 11 10 18 1 3 2 1 0 0
40-30 CTX-M-27 4 2 3 2 7 5 2 0 0
Others 18 8 8 2 4 2 2 8 12
Total E. coli 33 20 29 5 14 9 5 8 12
K. pneumoniae tonB
tonB39 CMY-2 1 1 1 0 0 0 0 0 0
tonB39 FOX-5 1 1 1 0 0 0 0 0 0
Others 10 4 6 2 5 2 3 4 5
Total K. pneumoniae 12 6 8 2 5 2 3 4 5
Overall total 45 26 37 7 19 11 8 12 17
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prior to subsequent infections was an independent risk factor for subsequent resistant
infections (9). Another recent study conducted in adults with bacteremia caused by
ESBL E. coli and Klebsiella spp. found that deﬁnitive treatment of the index infections
with ﬂomoxef (an oxacephem or fourth-generation cephalosporin) was an independent
risk factor for recurrence (11). In this study, we were able to examine only antibiotic use
prior to the index infection, and while overall antibiotic use in the 30 days prior to index
infections was not an independent risk factor for subsequent resistant infections,
patients who received prophylaxis prior to the index infections were twice as likely to
have subsequent ESC-R infections than patients who did not receive prophylaxis, even
after adjusting for underlying medical conditions and other potential confounders.
There are several possible explanations for this observation. First, given the prolonged
nature of the prophylactic regimens included in this analysis, patients who received
prophylaxis in the 30 days prior to the index infections likely continued to receive it
after the index infections, leading to ongoing selective pressure on the intestinal
microbiome and resulting in a greater susceptibility to resistant infections. Alterna-
tively, this observation might be a result of residual confounding due to underlying
urologic conditions, as children with urological abnormalities often experience recur-
rent UTIs and thus receive prophylaxis. Unfortunately, we did not have a sufﬁcient
number of subjects to be able to differentiate between urologic and other underlying
medical conditions in our multivariable model. The type of antimicrobial used for
prophylaxis is also likely important; one previous study found that among patients with
vesicoureteral reﬂux, children who received cephalosporin prophylaxis were more likely
to have breakthrough ESBL urinary tract infections than those who received prophylaxis
with co-trimoxazole (16). Again, our sample size precluded an examination of speciﬁc
prophylactic agents.
Consistent with other studies, 66% of subsequent isolates were concordant with the
index isolates (9, 11, 12). This ﬁnding suggests a persistent reservoir of resistant
bacteria, likely in the gastrointestinal tract or the genitourinary tract, which was not
eliminated during the treatment of the preceding infection. In our previous study, we
found that among the patients with stool and subsequent infection isolates available
for comparison, nearly half had stool and subsequent infection isolates that were both
concordant with the index isolates (9). Unfortunately, stool isolates were not included
in this study. Nevertheless, to reduce the risk of subsequent infections, persistent
reservoirs may need to be addressed therapeutically; fecal transplantation may be such
an intervention for intestinal reservoirs, while surgical interventions or maneuvers to
promote thorough bladder drainage may be required for urinary reservoirs.
While the majority of subsequent isolates were concordant with the index isolates,
we observed instances where subsequent isolates differed from the index isolates by
fumC-ﬁmH or tonB types but shared resistance determinants, suggesting possible
transfer of plasmids between organisms of the same or different species within a
patient, presumably due to ongoing selective pressure due to antibiotic exposure. We
also observed instances where subsequent isolates differed from the index isolates
both by fumC-ﬁmH or tonB types and by resistance determinants, suggesting the
vulnerability of the patient to the acquisition of new resistant organisms, presumably
due to ongoing dysbiosis with or without selective pressure.
We observed that a higher proportion of patients with ESC-R K. pneumoniae index
infections experienced subsequent infections than those with ESC-R E. coli index
infections, similar to previous ﬁndings (9, 17). This observation may be due to differ-
ences in host factors, as patients with ESC-R K. pneumoniae are more likely than those
with ESC-R E. coli to have hospital-acquired infections or previous health care exposure
and/or chronic medical conditions (18, 19). Finally, we observed an especially high rate
of concordance (71%) among patients with index infections with the ST131-associated
E. coli type 40-30 strain. This clone, which has spread rapidly to become the dominant
cause of multidrug-resistant extraintestinal E. coli infections in many populations (18,
20), has been shown to persist clinically irrespective of host factors and appropriate
antibiotic treatment (21).
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This study has several limitations. First, it was designed only to capture subsequent
infections that were detected at the study hospitals; therefore, our infection data may
be incomplete. However, our observed rate of subsequent infections (14%) is similar to
other pediatric studies that have reported rates of 17 to 18%. Similarly, we were limited
by our incomplete capture of antibiotic exposure; we did not capture antibiotic use that
occurred outside the study hospitals or that occurred after the index infections. This
may have resulted in an underestimate of true exposure. It is also possible that our
deﬁnition for UTI captured patients who had colonizations with ESC-R organisms rather
than true infections; however, given that most patients met microbiological criteria and
had signs and symptoms of UTI, we believe that the misclassiﬁcation of colonization as
a UTI was likely infrequent. Further, the study was not of sufﬁcient power to adjust for
speciﬁc medical conditions, which may have resulted in residual confounding. Finally,
some variability in resistance genotype proﬁles (speciﬁcally, patients with 1 isolate each
that was negative for a speciﬁc resistance determinant but was otherwise concordant)
may have been due to plasmid loss during the freeze/thaw cycles of archival storage.
This study also had several strengths, including its multicenter multiyear design,
relatively large sample size, and combination of detailed clinical and molecular data.
Antibiotic prophylaxis may contribute to the risk of subsequent ESC-R infections in
children, and in most cases, the molecular proﬁles of index and subsequent isolates are
concordant. These ﬁndings highlight the need to study antimicrobial stewardship
interventions in children requiring prophylaxis and assess emerging therapies, such as
fecal microbiota transplantation, to identify effective strategies for preventing recurrent
ESC-R infections.
MATERIALS AND METHODS
Setting and institutional review. This prospective surveillance study involved four freestanding
pediatric hospitals in the United States. The institutional review board at each hospital approved the
study protocol.
Subjects and study isolates. Between 1 September 2009 and 30 September 2013, participating
hospitals collected all candidate ESC-R E. coli, K. pneumoniae, and K. oxytoca isolates recovered from urine
or other normally sterile sites during routine clinical care of hospitalized and outpatient children 22
years of age. Candidate ESC-R isolates included those nonsusceptible (resistant or intermediate) to
aztreonam, ceftazidime, ceftriaxone, cefotaxime, or cefepime. Each hospital used its standard clinical
microbiological methods for species identiﬁcation and susceptibility testing. Isolates were archived
at 70°C and shipped to the coordinating center quarterly.
Coordinating center methods for conﬁrmation and characterization of study isolates. (i)
Overview. Upon arrival from participating laboratories, candidate resistant isolates were further evalu-
ated at the coordinating center using standardized methods to conﬁrm species and antibiotic suscep-
tibility and to characterize resistance phenotype and genotype as described below.
(ii) Identiﬁcation. Study isolates were identiﬁed to the species level using the Vitek card for
identiﬁcation of Gram-negative organisms (GN ID card; bioMérieux).
(iii) Antibiotic susceptibility testing. Antibiotic susceptibility was determined by disk diffusion. All
isolates were tested for susceptibility to ampicillin, amoxicillin-clavulanic acid, cefazolin, cefuroxime,
ceftazidime, ceftriaxone, cefepime, meropenem, piperacillin-tazobactam, ciproﬂoxacin, gentamicin, and
sulfamethoxazole-trimethoprim. The cephalosporin breakpoints recommended in 2010 (22) and carbap-
enem breakpoints recommended in 2011 (23) were applied to all candidate resistant isolates to conﬁrm
resistance.
(iv) Phenotypic characterization. The class A ESBL phenotype and class C AmpC phenotype were
identiﬁed as previously described (5, 9, 18). Carbapenem resistance was conﬁrmed in those isolates
identiﬁed as nonsusceptible to meropenem using disk diffusion as previously described (18). Control
strains included CLSI-recommended type strains E. coli ATCC 25922 and K. pneumoniae ATCC 700603, two
laboratory-characterized strains, an E. coli strain containing blaCMY-2, and a K. pneumoniae strain contain-
ing blaKPC.
(v) Resistance genotyping. Study isolates were tested by PCR using primer sets for genes encoding
common extended-spectrum cephalosporinases, including class A CTX-M, extended-spectrum TEM and
SHV, and class C CMY, DHA, and FOX as previously described (5, 9, 18, 24–27). Isolates exhibiting
phenotypic resistance to carbapenems were tested with primers for bla genes encoding class A (KPC),
class B (IMP, VIM, and NDM), and class D (OXA-48/181-like) carbapenemases as previously described (9,
18, 28). All amplicons were sequenced, and assembly and alignment of nucleotide sequences was
performed to identify all bla determinants to the variant level (e.g., CTX-M-15 versus CTX-M-14), as
previously described (5, 9, 18).
(vi) Sequence-based strain typing. To characterize clonal relatedness of ESC-R strains, PCR and
sequencing were carried out using previously described primers for fumC and ﬁmH for E. coli or for tonB
for K. pneumoniae (5, 9, 18, 29, 30).
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Deﬁnitions. “Index isolate” signiﬁes the ﬁrst ESC-R E. coli or Klebsiella sp. isolated from a patient during
the study period. “Subsequent isolate” signiﬁes an ESC-R E. coli or Klebsiella sp. isolate obtained28 days after
any prior isolate during the study period. Our goal in choosing this 28-day window was to select a time
point when patients would have completed treatment for the prior infections and after which any
infections occurring would likely be new infections rather than a continuation of previous infections.
Subsequent isolates were classiﬁed as either concordant or discordant. “Concordant subsequent
isolate” signiﬁes an isolate where the species, fumC-ﬁmH type for E. coli or tonB type for K.
pneumoniae, and molecular resistance determinants were the same as those for the index isolate.
“Discordant subsequent isolate” signiﬁes an isolate in which any of these characteristics differed
from that of the index isolate.
Clinical data. Demographic and clinical data were collected from the medical records using a
standardized case report form. Data on complex chronic conditions expected to last at least 12 months
and require frequent or specialty medical care were collected and categorized using the strategy
developed by Feudtner et al. using International Classiﬁcation of Diseases, 9th revision (ICD-9) diagnosis
codes (31). Additionally, we added a “urological” category that included neurogenic bladder and
vesicoureteral reﬂux. For patients who contributed urine isolates, symptom and culture data (collection
method, CFU per ml, etc.) were collected. These data were used by the coordinating site to characterize
patients as likely having a UTI. Given the heterogeneity of our patient population, which included infants,
patients with neurogenic bladders, and immunocompromised patients with neutropenia, it would be
difﬁcult to develop a highly sensitive and speciﬁc deﬁnition for UTI. Therefore, patients met criteria for
likely UTI if the culture met standard microbiology lab criteria for susceptibility testing (10,000
CFU/ml in a clean catch specimen or indwelling catheter or 1,000 CFU/ml in a straight catheter
specimen) (32) and/or the patient had symptoms of a UTI (presence of fever, abdominal/ﬂank pain,
vomiting, change in color or odor of urine, change in continence pattern, hematuria, dysuria, or
frequent/urgent urination).
Antibiotic exposure. Given the nature of the study, only antibiotic exposures in the year prior to the
index infections were collected. These exposures included all systemic (i.e., oral or intravenous) inpatient
and outpatient antibiotic treatments and prophylaxes. Outpatient treatment and prophylaxis data were
collected from pharmacy records or clinical chart notes and recorded using the case report form.
Inpatient antibiotic treatment data were obtained from the Pediatric Health Information System (PHIS)
database as previously described (5). Antibiotics were categorized as treatment or prophylaxis as
indicated in the medical record. We deﬁned “any antibiotic exposure” as receipt of any antibiotic
(whether treatment or prophylaxis). We deﬁned “prophylactic antibiotic exposure” as receipt of a
long-term prophylactic regimen of daily oral antibiotics; short courses, such as 2 to 7 day courses, for
surgical site infection prophylaxis were excluded. Prophylactic antibiotics that were administered 2 to 3
days per week (e.g., trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis) were considered as
administered daily as long as the regimen continued. A breakdown of antibiotic exposures (any antibiotic
and prophylaxis) by each class and/or individual antibiotic is provided in Table S1 in the supplemental
material.
Statistical analyses. We ﬁrst described and compared demographic and clinical variables between
patients with one ESC-R infection and patients with subsequent ESC-R infections. The chi-square or Fisher
exact test was used to compare categorical variables and a Mann-Whitney U test was used for continuous
variables. Subcategories of underlying medical conditions, immunosuppressants, and indwelling devices
were initially described but were later collapsed for the multivariable model due to small sample size. An
“immunosuppression” variable was created that included diagnosis of cancer, receipt of immunosup-
pressants within the year prior to the index infection, or receipt of hematopoietic cell or solid organ
transplantation.
Exposures to “any” and “prophylactic” antibiotics in the 30 days prior to the index infection were
tabulated for patients with and those without subsequent infections. The impact of antibiotic exposure
was then further explored using two Cox proportional hazards models: one with any antibiotic use in the
30 days prior to the index infection (whether prophylaxis or treatment indicated) as the predictor of
interest and one limited to prophylaxis use in the 30 days prior to the index infection as the predictor
of interest. Potential confounders were chosen a priori using a conceptual framework (see Fig. S1) and
included immunosuppression, underlying medical condition, indwelling device, and previous hospital-
ization.
We also described and compared microbiological and molecular characteristics of index isolates
between patients with one ESC-R infection and patients with subsequent ESC-R infections. Descriptive
statistics for resistance phenotypes, molecular resistance determinants, and fumC-ﬁmH type (E. coli) or
tonB type (K. pneumoniae) were tabulated and summarized. The associations between dichotomous
variables were evaluated using chi-square or Fisher exact tests.
Finally, we compared the microbiological and molecular characteristics of subsequent ESC-R isolates
with those of index isolates. The duration between the index and ﬁrst subsequent infections was also
described. All statistical analyses were performed using Stata (version 12.1; StataCorp, College
Station, TX).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
AAC.02656-16.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.5 MB.
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